

**STATE OF MISSOURI  
MISSOURI BOARD OF PHARMACY**

IN RE:	)	
	)	
MALLORY PARADIS	)	Complaint No. 2021-000080
License No. 2013037638	)	
250 W. 2 <sup>nd</sup> Street, Apt. 4102	)	
Kansas City, MO 64105	)	

**SETTLEMENT AGREEMENT BETWEEN THE  
MISSOURI BOARD OF PHARMACY AND MALLORY PARADIS**

Come now Mallory Paradis, R.Ph. ("Respondent" or "Licensee") and the Missouri Board of Pharmacy ("Board" or "Petitioner") and enter into this Settlement Agreement for the purpose of resolving the question of whether Respondent's license to practice pharmacy will be subject to discipline.

Pursuant to the terms of Section 536.060, RSMo, the parties hereto waive the right to a hearing by the Administrative Hearing Commission of the State of Missouri and, additionally, the right to a disciplinary hearing before the Board under Section 621.110, RSMo, and stipulate and agree that a final disposition of this matter may be effectuated as described below.

Respondent acknowledges that she understands the various rights and privileges afforded her by law, including the right to a hearing of the charges against her; the right to appear and be represented by counsel; the right to have all charges against her proven upon the record by competent and substantial evidence; the right to cross-examine any witnesses appearing at the hearing against her; the right to a decision upon the record by a fair and impartial administrative hearing commissioner concerning the charges pending against her and, subsequently, the right to a disciplinary hearing before the Board at which time she may present evidence in mitigation of discipline; and the right to recover attorney's fees incurred in defending this action against her license. Being aware of these rights provided her by operation of law, Respondent knowingly and

voluntarily waives each and every one of these rights and freely enters into this Settlement Agreement and agrees to abide by the terms of this document as they pertain to her.

Respondent acknowledges that she has received a copy of the draft Complaint to be filed with the Administrative Hearing Commission, the investigative report, and other documents relied upon by the Board in determining there is cause for discipline against Respondent's license.

For the purpose of settling this dispute, Respondent stipulates that the factual allegations contained in this Settlement Agreement are true and stipulates with the Board that Respondent's license to practice pharmacy, numbered 2013037638, is subject to disciplinary action by the Board in accordance with the provisions of Chapter 621 and Chapter 338, RSMo.

### **JOINT STIPULATION OF FACTS**

1. The Board is an agency of the State of Missouri created and established pursuant to §338.110, RSMo<sup>1</sup>, for the purpose of executing and enforcing the provisions of Chapter 338, RSMo.

2. Respondent is licensed as a pharmacist under the laws of the State of Missouri, License No. 2013037638. Respondent's license was at all times relevant herein current and active.

3. Respondent was Pharmacist-in-Charge ("PIC") at Hy-Vee Pharmacy #1322, 5330 NW 64<sup>th</sup> St., Kansas City, MO 64151 (the "Pharmacy").

4. On January 14, 2021, the Board received a Pharmacist Disciplinary Action Report from the Pharmacy stating that Respondent was terminated on January 14, 2021 for taking an alprazolam prescription home without paying the copay until a few days later, and that she had created a refill for alprazolam without physician approval.

---

<sup>1</sup> All statutory references are to the Revised Statutes of Missouri 2016, as amended, unless otherwise stated.

5. The Board investigated the report it received from the Pharmacy.
6. During its investigation, the Board reviewed Respondent's prescription history which showed that Respondent often filled four of her prescriptions early, resulting in a surplus of days' supply dispensed compared to the days' supply elapsed.
7. Between February 6, 2020 and January 2, 2021, a 420 days' supply of alprazolam 0.5mg, a Schedule IV controlled substance, was dispensed over a 332-day period.
8. Between February 12, 2020 and December 29, 2020, a 420 days' supply of amphetamine-dextroamphetamine 20mg, a Schedule II controlled substance, was dispensed over a 322-day period.
9. Between February 18, 2020 and January 21, 2021, a 450 days' supply of Duloxetine 30mg was dispensed over a 339-day period.
10. Between February 12, 2020 and December 29, 2020, a 390 days' supply of Vyvanse 60mg, a Schedule II controlled substance, was dispensed over a 322-day period.
11. With regard to Respondent's alprazolam prescription, Respondent filled 60-tablet prescriptions for alprazolam 0.5mg on November 2, 2020, November 19, 2020, December 7, 2020, and December 30, 2020.
12. The November 19, 2020 prescription was filled two weeks early.
13. On December 7, 2020, Respondent completed a refill authorization for Respondent's alprazolam prescription and indicated it was "verbal per Samantha [Durland]" with zero additional refills "NTBS."
14. Respondent completed the receipt, data entry, drug utilization review and pre-verification for the December 7, 2020 alprazolam refill, prescription no. 490274, at 7:29am, before the Pharmacy opened.

15. Respondent did not speak with Dr. Durland the morning of December 7, 2020.
16. Respondent does not recall with whom she spoke at Dr. Durland's office, the circumstances, or when she obtained the verbal authorization for the refill, but acknowledges it was not on December 7, 2020.
17. Later in the day on December 7, 2020, Respondent rang up the prescription along with her own grocery purchases while in the presence of two other pharmacy employees.
18. The December 7, 2020 refill of the alprazolam prescription was two weeks early.
19. The Pharmacy received an electronic prescription for alprazolam for Respondent on December 29, 2020.
20. A pharmacist conducted a Drug Utilization Review (DUR) on this prescription at 7:23am on December 30, 2020. The pharmacist declined the prescription during this DUR because it was last filled on December 7 and too early to refill until January 4, 2021.
21. At 10:04pm that same day, Respondent conducted another DUR and pre-verification of the prescription, and dispensed the alprazolam, prescription no. 494777, to herself at 10:15pm
22. Respondent then put prescription no. 494777 in her backpack and did not pay for the prescription before she left the store that night.
23. Respondent's fiancé paid for prescription no. 494777 on January 2, 2021.
24. The December 30, 2020 alprazolam prescription was filled six days early.
25. Respondent participated in the March 1, 2020 refilling of prescription no. 430560, the March 26, 2020 original fill of prescription no. 441628, the July 16, 2020 original and August 14, 2020 refill of prescription no. 460855, the November 2, 2020 original and November 19, 2020 refill of prescription no. 483147, the December 7, 2020 original fill of prescription no. 490274,

and the December 30, 2020 original fill of prescription no. 494777. All of these prescriptions were for alprazolam.

26. Hy-Vee's policy states the following with regard to Work Expectations and Discipline:

No list of unacceptable performance or misconduct can be complete, but the following are examples of behaviors and conduct that will lead to discipline, up to and including termination of employment:

Theft or fraud, including removal of company property without authorization and theft of time;

Consumption or use of products without a paid receipt;

Checking out family members, friends or oneself.

27. All of the above-referenced violations committed by the Pharmacy and its staff may be imputed to Respondent, who is charged with the responsibility to ensure that the Pharmacy is operated in full compliance with all state and federal laws and regulations concerning the practice of pharmacy. §338.210.5, RSMo.

28. As PIC, Respondent's failure to assure full compliance with state and federal pharmacy laws and regulations is in violation of 20 CSR § 2220-2.090(2)(E), (H), (N), (P), (U) and (W) which state in pertinent parts:

2. The responsibilities of a pharmacist-in-charge, at a minimum, will include:

\* \* \*

(E) Assurance that all procedures of the pharmacy in the handling, dispensing and recordkeeping of controlled substances are in compliance with state and federal laws;

\* \* \*

(H) The prescription files are maintained according to the requirements of this board and the other state and federal controlled substance laws and regulations;

\* \* \*

(N) The pharmacist-in-charge will be responsible for the supervision of all pharmacy personnel, to assure full compliance with the pharmacy laws of Missouri;

\* \* \*

(P) Policies and procedures are in force to insure safety for the public concerning any action by pharmacy staff members or within the pharmacy physical plant;

\* \* \*

(U) Assure that the appropriate handling and disposal of controlled substances is done and verified through appropriate documentation;

\* \* \*

(W) Assure full compliance with all state and federal drug laws and rules;

29. As PIC of the Pharmacy, Respondent's conduct, herein described, is in violation of 20 CSR § 2220-2.090.

### **JOINT CONCLUSIONS OF LAW**

30. Respondent's conduct is cause for disciplinary action against her pharmacist license under § 338.055.2(5) and (13), RSMo, which provides:

2. The board may cause a complaint to be filed with the administrative hearing commission as provided by chapter 621, RSMo, against any holder of any certificate of registration or authority, permit or license required by this chapter or any person who has failed to renew or has surrendered his or her certificate of registration or authority, permit or license for any one or any combination of the following causes:

\* \* \*

(5) . . . misconduct, . . . [or] misrepresentation in the performance of the functions or duties of any profession licensed or regulated by this chapter;

\* \* \*

(13) Violation of any professional trust or confidence;

## **JOINT AGREED DISCIPLINARY ORDER**

A. Based upon the foregoing, the parties mutually agree and stipulate that the following shall constitute the disciplinary order entered by the Board in this matter under the authority of §621.045.4(3), RSMo. Respondent's pharmacist license, number 2013037638 shall be placed on **PROBATION for a period of TWO (2) YEARS** ("disciplinary period"). The terms of discipline shall be:

**The following terms apply for the entire disciplinary period.**

1. Respondent shall comply with all applicable provisions of Chapter 338, Chapter 195, Chapter 196 and all applicable federal and state pharmacy/drug laws and regulations and all federal and state criminal laws. "State" here includes the State of Missouri and all other states and territories of the United States.
2. Respondent shall not serve as pharmacist-in-charge or manager-in-charge of any entity licensed or regulated by the Board, or as a preceptor for pharmacy interns or as a teaching member of any school or college of pharmacy. Additionally, Respondent shall not serve as a consultant required by a Board disciplinary order for any pharmacy/drug distributor.
3. Respondent shall keep the Board apprised of her current home, electronic mail (e-mail) and work addresses and telephone numbers. Respondent shall notify the Board of any change in Respondent's employer or Respondent's home or work address within ten (10) days of such change in a manner approved by the Board. For employer/work changes, Respondent's notification shall include the reasons for the change. If at any time Respondent is employed by a temporary employment agency or maintains employment that requires frequent daily or weekly changes of work location she must provide the Board a list of locations worked if requested by the Board or Board's representative.
4. If Respondent's license expires or becomes void/invalid, upon renewal or reapplication, Respondent's license shall be subject to all terms and conditions of discipline not previously satisfied, including any remaining suspension/probationary period.
5. Respondent shall cooperate with the Board's monitoring and investigation of Respondent's compliance with the terms and conditions of this Settlement Agreement. Respondent shall make herself available for personal interviews to be conducted by a member of the Board or the Board of Pharmacy staff. Said meetings shall be at the Board's discretion and may occur periodically during the disciplinary period.
6. Respondent shall respond to any written inquiry of the Board and provide any requested documentation/records within three (3) days of receipt of a written request from the

Board or the Board's authorized designee, or as otherwise requested by the Board/Board designee.

7. If requested by the Board, Respondent shall submit to a criminal history background check via the Board's approved vendor at Respondent's cost. Unless otherwise directed by the Board, Respondent shall submit the required fingerprints and undergo the requested criminal history background check within ten (10) days of the Board's request.
8. Respondent shall submit to any drug, alcohol or urinalysis testing requested by the Board, at Respondent's cost. Testing may be conducted on any human sample, including, but not necessarily limited to, urine, blood, breath, hair, nails, skin or saliva. The timing, manner and scheduling for testing is within the Board's sole discretion.
9. Respondent shall report any of the following occurrences to the Board, in writing, within seventy-two (72) hours of such occurrence:
  - a. Any arrest or issuance of a criminal complaint;
  - b. Any municipal/local arrest, citation or complaint relating to drugs, theft, shoplifting, burglary, possession of drug paraphernalia, driving or operating a motor vehicle under the influence/while intoxicated or illegally possessing, selling or purchasing alcohol, any drug or drug paraphernalia;
  - c. A finding or plea of guilty or nolo contendere in any state or federal criminal proceeding to any criminal complaint, information or indictment, including, but not limited to, any deferred or diverted adjudication, order or agreement;
  - d. A conviction of any crime, including, but not limited to, any Suspended Imposition of Sentence ("SIS") or Suspended Execution of Sentence ("SES");
  - e. A finding by a court that Respondent has violated any term of her criminal probation/parole;
  - f. Any discipline, citation, or other administrative action filed or taken against Respondent by any state board/committee of pharmacy, or any other state or federal agency.

Failure to timely report any of the foregoing occurrences shall be considered a disciplinary violation.

10. If Respondent is currently or begins serving any period of criminal probation/parole, Respondent shall provide the name of her probation/parole officer to the Board, in writing, within ten (10) days of the effective date of this Agreement or within ten (10) days of the designation of a probation/parole officer. If Respondent's probation/parole officer is changed for any reason, Respondent shall submit the name of the replacement officer to the Board within ten (10) days of the change/modification. Respondent shall execute a release authorizing her probation or parole officer to provide to the Board any information relating to Respondent's probation or parole. Respondent shall maintain the release in effect and shall provide an updated release if requested by the Board.



11. Respondent shall file a "Disciplinary Compliance Report" with the Board in a form/manner approved by the Board. The Disciplinary Compliance Report shall be due by January 1 and July 1 of each calendar year. Respondent's final Disciplinary Compliance Report shall be filed no later than ninety (90) days before the end of the probationary period.
12. Respondent shall not be personally involved in any aspect of a pharmacy's processing, dispensing, or billing of any prescription for herself or any family member, including, but not limited to, recording any telephone prescription or verbal refill authorization.
13. Respondent's failure to comply with any condition of discipline set forth herein constitutes a violation of this Agreement.
14. The parties to this Agreement understand that the Board of Pharmacy will maintain this Agreement as an open record of the Board as provided in Chapters 324, 338, 610, RSMo.

#### **NOTICE TO EMPLOYERS**

15. If applicable, Respondent shall notify any employer of the employer's need to apply for and receive the necessary state (misdemeanor/felony) and federal (felony) waivers from the Bureau of Narcotics and Dangerous Drugs and the Drug Enforcement Administration in order to be employed within a facility that maintains state or federal registrations for the purpose of storing, distributing or dispensing controlled substances.
16. Except as otherwise provided herein, "Employment" within the meaning of this Agreement shall include any full-time, part-time, temporary, relief or pharmacy management service as a pharmacist or any position for which a pharmacist license, pharmacy intern license or pharmacy technician registration is a requirement or criterion for employment, regardless of whether Respondent is an employee, independent contractor, volunteer, instructor or consultant. "Employment" shall also include any entity where legend drugs are stored, sold, dispensed or distributed.
17. Respondent shall notify any current or future employers of this action by providing a copy of this Settlement Agreement to the pharmacist-in-charge or manager-in-charge of any pharmacy or drug distributorship where Respondent is employed, on or before the effective date of discipline or prior to accepting any offer of employment.
  - a. If Respondent is not or will not be employed by a pharmacy or drug distributor, the notice shall be provided to Respondent's direct supervisor at Respondent's current/prospective place of employment, as defined herein, within the timeframes required by this section.
  - b. For purposes of this Agreement, a pharmacy shall also include, but is not limited to, any location providing pharmacy services for inpatients of a licensed hospital or residents of a long term care facility.
18. Respondent shall cause the pharmacist-in-charge, manager-in-charge or supervisor to sign a written acknowledgment on a form approved by the Board indicating that he/she

has received and reviewed the Settlement Agreement and the terms and conditions imposed thereby. The written acknowledgement shall be signed and dated by the applicable pharmacist-in-charge, manager-in-charge or supervisor and shall be submitted to the Board by Respondent for verification within ten (10) days of the dated signature. Respondent shall be responsible for ensuring the required signed acknowledgments are timely submitted to the Board.

19. If at any time Respondent is employed by a temporary employment agency, Respondent must provide each employment agency a copy of this Settlement Agreement prior to being assigned to a temporary employment site. Respondent shall also provide a copy of the Settlement Agreement to each pharmacist-in-charge or manager-in-charge of each pharmacy or drug distributor where Respondent is assigned to work. If the pharmacist-in-charge or manager-in-charge is not present at the employment site, a copy of the Settlement Agreement shall be left at the applicable site for the pharmacist-in-charge/manager-in-charge to review. Respondent shall provide an accurate listing of all employment/work sites where Respondent has been assigned if requested by the Board or the Board's authorized designee.
20. Licensee shall execute any release or provide any authorization necessary for the Board to obtain records of Respondent's employment during the period covered by this Settlement Agreement.

#### **CONTINUING EDUCATION**

21. Within three (3) months of the effective date of this Settlement Agreement, Respondent shall take and pass the Board approved Pharmacy Practice Guide Continuing Education Examination, if available. Respondent shall register and complete the required examination via the Board's website or as otherwise requested by the Board.
22. Respondent shall take a minimum of 6.0 continuing education (0.60 CEUs) hours in pharmacy law during each biennial pharmacist renewal period that is completed while Respondent is on discipline. The continuing education required by this section shall comply with 20 CSR 2220-7.080 and may be used to satisfy the licensee's biennial continuing education requirement. Proof of compliance with the continuing education requirements of this section shall be submitted to the Board on or before October 31<sup>st</sup> of each biennial pharmacist renewal period.

B. Upon the expiration of said discipline, Respondent's license as a pharmacist in Missouri shall be fully restored if all other requirements of law have been satisfied; provided, however, that in the event the Board determines that Respondent has violated any term or condition of this Agreement, the Board may, in its discretion, after an evidentiary hearing, vacate and set

aside the discipline imposed herein and may suspend, revoke or otherwise lawfully discipline Respondent.

C. If the Board determines that Respondent has violated a term or condition of this Settlement Agreement, which violation would also be actionable in a proceeding before the Administrative Hearing Commission or the circuit court, the Board may elect to pursue any lawful remedies or procedures afforded it and is not bound by this Settlement Agreement in its determination of appropriate legal actions concerning that violation. If any alleged violation of this Settlement Agreement occurred during the disciplinary period, the Board may choose to conduct a hearing before it either during the disciplinary period, or as soon thereafter as a hearing can be held to determine whether a violation occurred and, if so, it may impose further discipline. The Board retains jurisdiction to hold a hearing to determine if a violation of this Settlement Agreement has occurred.


D. No order shall be entered by the Board pursuant to the preceding paragraph of this Agreement without notice and an opportunity for hearing before the Board in accordance with the provisions of Chapter 536, RSMo.

E. The terms of this Settlement Agreement are contractual, legally enforceable, and binding, not merely recital. Except as otherwise contained herein, neither this settlement agreement nor any of its provisions may be changed, waived, discharged, or terminated, except by an instrument in writing signed by the party against whom the enforcement of the change, waiver, discharge, or termination is sought.

F. Respondent, together with her heirs and assigns, and her attorneys, do hereby waive and release, acquit and forever discharge the Board, its respective members and any of its employees, agents, or attorneys, including any former board members, employees, agents, and

attorneys, of, or from, any liability, claim, actions, causes of action, fees, costs and expenses, and compensation, including but not limited to, any claims for attorney's fees and expenses, including any claims pursuant to Section 536.087, RSMo, or any claim arising under 42 U.S.C. § 1983, which may be based upon, arise out of, or relate to any of the matters raised in this litigation, or from the negotiation or execution of this Settlement Agreement. The parties acknowledge that this paragraph is severable from the remaining portions of this Settlement Agreement in that it survives in perpetuity even in the event that any court of law deems this Settlement Agreement or any portion thereof void or unenforceable.

**RESPONDENT, AS EVIDENCED BY THE INITIALS ON THE APPROPRIATE LINE,**


 **REQUESTS**  
**DOES NOT REQUEST**

**THE ADMINISTRATIVE HEARING COMMISSION TO DETERMINE IF THE FACTS SET FORTH HEREIN ARE GROUNDS FOR DISCIPLINING RESPONDENT'S LICENSE.**


If Respondent has requested review, Respondent and Board jointly request that the Administrative Hearing Commission determine whether the facts set forth herein are grounds for disciplining Respondent's license and issue findings of fact and conclusions of law stating that the facts agreed to by the parties are grounds for disciplining Respondent's license. Effective fifteen (15) days from the date the Administrative Hearing Commission determines that the Settlement Agreement sets forth cause for disciplining Respondent's license, the agreed upon discipline set forth herein shall go into effect.

If Respondent has not requested review by the Administrative Hearing Commission, the Settlement Agreement goes into effect fifteen (15) days after the document is signed by the Board's Executive Director.

RESPONDENT  
MALLORY PARADIS

  
Mallory Paradis

Date: 11/5/2021


  
Michael Crawford #64799  
Attorney for Respondent

PETITIONER  
MISSOURI BOARD OF  
PHARMACY

By:   
Kimberly Grinston  
Executive Director

Date: 11-12-2021

NEWMAN, COMLEY & RUTH P.C.

By:   
Andrea Embrey Turner #48675  
601 Monroe Street, Suite 901  
P.O. Box 537  
Jefferson City, MO 65102-0537  
Telephone: (573) 634-2266  
Fax: (573) 636-3306  
turnera@ncrpc.com

Attorneys for Missouri Board of  
Pharmacy